Monitoreringen skal indledes før behandlingen initieres og gennemføres regelmæssigt herefter i indtil 8 uger efter behandlingen seponeres (se pkt.
Patients should be periodically monitored for hypomagnesaemia and accompanying hypocalcaemia prior to initiating Vectibix treatment, and periodically thereafter for up to 8 weeks after the completion of treatment (see section 4.8).